Alpha Tau is a medical device company that focuses on the development and commercialization of its Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of solid cancers.

The technology, which was developed at Tel Aviv University in 2003, enables a highly potent and conformal radiotherapy treatment using alpha-emitting atoms.

Directly inserted into the tumor, the Alpha DaRT seeds release a high-energy dose over a range of several millimeters, enabling a focal alpha-radiation treatment that spares the surrounding healthy tissue.

In 2017, Alpha Tau started with its first-in-human study of locally advanced and recurrent SCC cancers of the skin and head and neck, the results of which were subsequently published in the prestigious International Journal of Radiation Oncology | Biology | Physics.

Following these initial encouraging results, Alpha Tau substantially expanded its clinical evaluations in later trials to a much wider patient population.

The supportive data from these first trials also led to the FDA granting Breakthrough Device Designation to the Alpha DaRT for the treatment of patients with SCC of the skin or oral cavity without curative standard of care.

Later on, Alpha Tau also received FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM (glioblastoma multiforme).

Today, in partnership with a number of esteemed medical and educational institutions worldwide, Alpha Tau has commenced several clinical and pre-clinical studies which are presently ongoing, and is also currently evaluating other potential uses of the Alpha DaRT technology for indications such as breast, pancreas, lung, GBM and prostate cancers, as well as other applications such as combinations with immunotherapies.